Genitourinary Cancer News

SAN FRANCISCO – Sacituzumab govitecan showed activity in patients with relapsed or refractory metastatic urothelial carcinoma, including those treated with immune checkpoint inhibitors and those with visceral metastases, according to results of a phase 1/phase 2 study presented at Genitourinary Cancers Symposium.

SAN FRANCISCO — Pembrolizumab induced durable complete responses among patients with high-risk, nonmuscle-invasive, bacillus calmette-guérin-unresponsive bladder carcinoma in situ with or without papillary tumors, according to updated interim results from cohort A of the phase 2 KEYNOTE-057 trial presented at Genitourinary Cancers Symposium.

The FDA granted priority review for a supplemental biologics license application seeking approval of pembrolizumab in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma, according to a press release from the manufacturer.

The combination of pembrolizumab and axitinib extended OS and PFS compared with sunitinib as first-line treatment for patients with previously untreated advanced or metastatic clear-cell renal cell carcinoma, according to results of the randomized phase 3 KEYNOTE-426 clinical trial scheduled for presentation at Genitourinary Cancers Symposium.

Physicians treating certain types of cancers appeared more likely to prescribe a specific drug over other treatments if they received yearly payments from that drug’s manufacturer, according to results of a study published in The Oncologist.

Young adults in the U.S. demonstrated a higher risk for obesity-related cancers than previous generations, according to a study recently published in Lancet Public Health.

Association of Community Cancer Centers relaunched its Immuno-Oncology Institute to further support all aspects of immunotherapy integration.

Acute kidney injury appeared to be a common and considerable burden among patients receiving systemic treatment for cancer, according to a population-based study published in Journal of the National Cancer Institute.

Fecal microbiota transplantation may be a viable treatment option for patients with cancer who have developed immunotherapy-induced colitis, according to results of a case series published in Nature Medicine.

Although partial nephrectomy was associated with improved OS among patients with localized renal cancer, the survival advantage was less substantial among a subset of patients with tumors larger than 4 cm, according to study findings published in Cancer.